Syndax Pharmaceuticals (SNDX) Cash from Investing Activities (2015 - 2026)

Syndax Pharmaceuticals' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 59.22% year-over-year to $38.4 million; the TTM figure through Mar 2026 stood at $234.3 million (up 993.05% YoY), while the FY2025 annual figure was $290.0 million, up 231.97% from the prior year.
• Cash from Investing Activities was $38.4 million for Q1 2026 at Syndax Pharmaceuticals, down from $81.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $94.1 million in Q1 2025 to a low of -$269.0 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged $2.4 million across 5 years, with a median of $38.4 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 689.97% in 2023, then sank 1551.15% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$137.6 million in 2022, then soared by 88.16% to -$16.3 million in 2023, then tumbled by 1551.15% to -$269.0 million in 2024, then jumped by 130.33% to $81.6 million in 2025, then plunged by 52.94% to $38.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $38.4 million (Q1 2026), $81.6 million (Q4 2025), and $72.4 million (Q3 2025), per Business Quant data.